http://beam-alliance.eu/

Biotechs from Europe innovating in Anti-Microbial Resistance

The Challenge

The emergence of multi-drug resistant bacteria presents a global public health crisis which demands the development of new antibiotics, preventive or alternative strategies, yet the R&D investment from large pharmaceutical companies is on the wane due to lack of attractiveness of investment in this therapeutic area.

Innovation is thus largely driven by biotech companies, and European nations need to engage more extensively in supporting this innovation via new policies and R&D stimulating incentives.

Our Mission

The BEAM Alliance will work **to improve the regulatory, investment, and commercial environments** in Europe for research, development, approval and market viability of **new products combating antimicrobial resistance.**

• **Representing**
European biotech companies involved in developing innovative products to tackle antimicrobial resistance

• **Giving**
Members a unique voice to propose and support policies and incentives to identified issues in Europe

• **Collaborating**
With the existing community of stakeholders dedicated to implementing tangible solutions

• **Recommending**
Supportive incentives that warrant action by policymakers to stimulate innovation by biotech companies

The Alliance of 34 Biotechs in 10 European Countries



If you are a European biotech interested in joining the Alliance, please contact:
Marie BAUMIER, Da Volterra – marie.baumier@davolterra.com